Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects
NCT03949426
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus
Interventions
DRUG:
KPG-818
Sponsor
Kangpu Biopharmaceuticals, Ltd.